EG 101
Alternative Names: EG-101Latest Information Update: 15 Oct 2024
Price :
$50 *
At a glance
- Originator Evergreen Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Preeclampsia
Most Recent Events
- 10 Oct 2024 Preclinical trials in Preeclampsia in USA (unspecified route) prior to October 2024 (Evergreen Therapeutics pipeline, October 2024)
- 11 Apr 2022 Shenzhen Eglin Pharmaceutical has patent protection for EG 101 (Evergreen Therapeutics pipeline, April 2022)
- 11 Apr 2022 Preclinical trials in Preeclampsia in China (unspecified route) (Evergreen Therapeutics pipeline, April 2022)